4-''O''-Methylhonokiol
4-O-Methylhonokiol
|
Names |
IUPAC name
2-(4-Methoxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol |
Other names
3,5′-Diallyl-2′-hydroxy-4-methoxybiphenyl |
Identifiers |
|
|
|
|
ChemSpider |
|
|
|
InChI=1S/C19H20O2/c1-4-6-14-8-10-18(20)17(12-14)15-9-11-19(21-3)16(13-15)7-5-2/h4-5,8-13,20H,1-2,6-7H2,3H3 Key: OQFHJKZVOALSPV-UHFFFAOYSA-N InChI=1/C19H20O2/c1-4-6-14-8-10-18(20)17(12-14)15-9-11-19(21-3)16(13-15)7-5-2/h4-5,8-13,20H,1-2,6-7H2,3H3 Key: OQFHJKZVOALSPV-UHFFFAOYAP
|
COC1=C(C=C(C=C1)C2=C(C=CC(=C2)CC=C)O)CC=C
|
Properties |
|
C19H20O2 |
Molar mass |
280.37 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Infobox references |
|
|
4-O-Methylhonokiol is a neolignan, a type of phenolic compounds. It is found in the bark of Magnolia grandiflora[1] and in M. virginiana flowers.[2]
4-O-Methylhonokiol is a potent CB2 receptor ligand (Ki = 50 nM), showing a unique inverse agonism and partial agonism via different pathways (cAMP and Ca2+) and potently inhibits osteoclastogenesis.[3] 4-O-Methylhonokiol further attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway.[4] The different neuroprotective and anti-Alzheimer Disease effects reported in rodent models may be mediated via CB2 receptors, providing that the compound should be orally bioavailable to the brain.[5] It was shown that 4-O-methylhonokiol activates CB2 receptors and also inhibits the oxygenation of the major endocannabinoid 2-AG via COX-2 in a substrate-selective manner, thus leading to potential synergistic effects at CB receptors.[6] The same study also provided data that this natural product can readily pass the blood–brain barrier, using LC-MS/MS.
References
- ↑ Clark, Alice M.; El-Feraly, Arouk S.; Li, Wen-Shyong (1981). "Antimicrobial activity of phenolic constituents ofmagnolia grandiflora L". Journal of Pharmaceutical Sciences. 70 (8): 951–2. PMID 7310672. doi:10.1002/jps.2600700833.
- ↑ Chandra, Amitabh; Nair, Muraleedharan (2007). "Supercritical Carbon Dioxide Extraction and Quantification of Bioactive Neolignans fromMagnolia virginianaFlowers". Planta Medica. 61 (2): 192–5. PMID 7753933. doi:10.1055/s-2006-958051.
- ↑ Schuehly, Paredes; Kleyer, Huefner; Anavi-Goffer, Raduner; Altmann, Gertsch (2011). "Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.". Chemistry and Biology. 18: 1053–64. PMID 21867920. doi:10.1016/j.chembiol.2011.05.012.
- ↑ Lee, Y. J.; Choi, I. S.; Park, M. H.; Lee, Y. M.; Song, J. K.; Kim, Y. H.; Kim, K. H.; Hwang, D. Y.; Jeong, J. H.; Yun, Y. P.; Oh, K. W.; Jung, J. K.; Han, S. B.; Hong, J. T. (2011). "4-O-Methylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway". Free Radical Biology and Medicine. 50 (1): 66–77. PMID 20974250. doi:10.1016/j.freeradbiomed.2010.10.698.
- ↑ Gertsch, Anavi-Goffer (2012). "Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors?". Journal of Neuroinflammation. 9 (135): 1053–64;. doi:10.1186/1742-2094-9-135.
- ↑ Chicca, A.; Gachet, M. S.; Petrucci, V.; Schuehly, W.; Charles, R. -P.; Gertsch, J. R. (2015). "4′-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation". Journal of Neuroinflammation. 12. doi:10.1186/s12974-015-0307-7.
|
---|
Lignans | |
---|
Lignan glycosides | |
---|
Mammalian lignans (enterolignans) | |
---|
Neolignans | |
---|
Flavonolignans |
- Cinchonain-Ib
- Dehydrosilybin
- Deoxysilycistin
- Deoxysilydianin
- Hydnocarpin
- Hydnowightin
- Neosilyhermin
- Palstatin
- Rhodiolin
- Salcolin A
- Salcolin B
- Scutellaprostin A, B, C, D, E and F
- Silandrin
- Silyamandin
- Silibinin
- Silybinome
- Silicristin
- Silydianin
- Silyhermin
- Tricin 4'-O-(erythro-beta-guaiacylglyceryl) ether
- Tricin 4'-O-(threo-beta-guaiacylglyceryl) ether
|
---|
|
---|
Receptor (ligands) | CB1 |
- Antibodies: Brizantin (Бризантин)
- Dietressa (Диетресса)
|
---|
CB2 |
- Agonists: 2-AG
- 2-AGE (noladin ether)
- 3,3'-Diindolylmethane
- 4-O-Methylhonokiol
- α-Amyrin
- β-Amyrin
- A-796,260
- A-834,735
- A-836,339
- AM-1172
- AM-1221
- AM-1235
- AM-1241
- AM-2232
- Anandamide
- AZ-11713908
- Cannabinol
- Caryophyllene
- CB-13
- CBS-0550
- CP-55,940
- GW-405,833 (L-768,242)
- GW-842,166X
- HU-308
- JTE 7-31
- JWH-007
- JWH-015
- JWH-018
- JWH-73
- JWH-133
- L-759,633
- L-759,656
- Magnolol
- MDA-19
- Nabitan
- NADA
- PF-03550096
- S-444,823
- SER-601
- Serinolamide A
- UR-144
- Tedalinab
- THC (dronabinol)
- THCV
- Tetrahydromagnolol
- Virodhamine
|
---|
GPR18 | |
---|
GPR55 | |
---|
GPR119 | |
---|
|
---|
Transporter (modulators) | |
---|
Enzyme (modulators) | FAAH | |
---|
MAGL | |
---|
ABHD6 |
- Inhibitors: JZP-169
- JZP-430
- KT182
- KT185
- KT195
- KT203
- LEI-106
- ML294
- ML295
- ML296
- UCM710
- WWL-70
|
---|
ABHD12 | |
---|
|
---|
Others |
- Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
- ARN-272 (FAAH-like anandamide transporter inhibitor)
|
---|
- See also
- Receptor/signaling modulators
- Cannabinoids (cannabinoids by structure)
|
|
---|
Alcohols | |
---|
Barbiturates | |
---|
Benzodiazepines | |
---|
Carbamates | |
---|
Flavonoids | |
---|
Imidazoles | |
---|
Kava constituents |
- 10-Methoxyyangonin
- 11-Methoxyyangonin
- 11-Hydroxyyangonin
- Desmethoxyyangonin
- 11-Methoxy-12-hydroxydehydrokavain
- 7,8-Dihydroyangonin
- Kavain
- 5-Hydroxykavain
- 5,6-Dihydroyangonin
- 7,8-Dihydrokavain
- 5,6,7,8-Tetrahydroyangonin
- 5,6-Dehydromethysticin
- Methysticin
- 7,8-Dihydromethysticin
- Yangonin
|
---|
Monoureides | |
---|
Neuroactive steroids | |
---|
Nonbenzodiazepines | |
---|
Phenols | |
---|
Piperidinediones | |
---|
Pyrazolopyridines | |
---|
Quinazolinones | |
---|
Volatiles/gases | |
---|
Others/unsorted |
- 3-Hydroxybutanal
- α-EMTBL
- AA-29504
- Avermectins (e.g., ivermectin)
- Bromide compounds (e.g., lithium bromide, potassium bromide, sodium bromide)
- Carbamazepine
- Chloralose
- Chlormezanone
- Clomethiazole
- DEABL
- Dihydroergolines (e.g., dihydroergocryptine, dihydroergosine, dihydroergotamine, ergoloid (dihydroergotoxine))
- DS2
- Efavirenz
- Etazepine
- Etifoxine
- Fenamates (e.g., flufenamic acid, mefenamic acid, niflumic acid, tolfenamic acid)
- Fluoxetine
- Flupirtine
- Hopantenic acid
- Lanthanum
- Lavender oil
- Lignans (e.g., 4-O-methylhonokiol, honokiol, magnolol, obovatol)
- Loreclezole
- Menthyl isovalerate (validolum)
- Monastrol
- Niacin
- Nicotinamide (niacinamide)
- Org 25,435
- Phenytoin
- Propanidid
- Retigabine (ezogabine)
- Safranal
- Seproxetine
- Stiripentol
- Sulfonylalkanes (e.g., sulfonmethane (sulfonal), tetronal, trional)
- Terpenoids (e.g., borneol)
- Topiramate
- Valerian constituents (e.g., isovaleric acid, isovaleramide, valerenic acid, valerenol)
- Unsorted benzodiazepine site PAMs: MRK-409 (MK-0343)
- TCS-1105
- TCS-1205
|
---|
See also: Receptor/signaling modulators • GABA receptor modulators |